siRNA‐Based Nanodrug Delivery Systems in the Treatment of Autoimmune Diseases
Journal of Immunology Research · 2026-01 · 2026 (1)
DOI: 10.1155/jimr/2307551 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 02.08.2026. Verfasst von Yi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated …. Hauptthemen laut MEDLINE: Autoimmune Diseases, RNA, Small Interfering, Drug Delivery Systems, RNAi Therapeutics. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Guangxi Zhuang Autonomous Region, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Autoimmune diseases are chronic disorders with complex pathogenesis. Immune homeostasis disruption is closely associated with disease initiation and progression. Despite extensive research, the precise mechanisms underlying these diseases remain elusive. Conventional therapeutic approaches for autoimmune diseases primarily involve the administration of immunosuppressants, glucocorticoids, and monoclonal antibodies, each of which presents certain limitations. The emergence of RNA interference (RNAi) therapeutics has introduced a novel avenue for addressing these conditions. The development of an optimally engineered vector for RNAi drugs is anticipated to significantly enhance their clinical applicability. Nanomaterials, as promising drug carriers, offer robust support for RNAi therapeutics. This review summarizes recent advances and applications of nanodelivery systems for small interfering RNA (siRNA) therapeutics in autoimmune disease treatment. It also analyzes the challenges and future prospects of nanomaterial application in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.…
- Department of Central Laboratory, Shenzhen Hospital (Longgang), Beijing University of Chinese Medicine, Shenzhen 518172, China, bucm.edu.cn.
ORCID-Profile: Yi Liu, Zhihui Feng, Biao Zhang, Xueli Yang, Fei Yang, Guiya Lu, Chunhong Li, Chune Mo, Minglin Ou, Xianliang Hou
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- Shenzhen Science and Technology Program
- Guilin Science Research and Technology Development Project
- Guangdong Province Medical Science and Technology Research Foundation
- Guangxi Medical and Health Appropriate Technology Development and Promotion Project
- National Natural Science Foundation of China
- Innovation Training Program for College Students
Zitieren
APA
Liu, Y., Feng, Z., Zhang, B., Yang, X., Yang, F., Lu, G., Li, C., Mo, C., Ou, M., & Hou, X. (2026). siRNA‐Based Nanodrug Delivery Systems in the Treatment of Autoimmune Diseases. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/2307551
Vancouver
Liu Y, Feng Z, Zhang B, Yang X, Yang F, Lu G, et al. siRNA‐Based Nanodrug Delivery Systems in the Treatment of Autoimmune Diseases. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/2307551
BibTeX
@article{Liu2026,
author = {Liu, Yi and Feng, Zhihui and Zhang, Biao and Yang, Xueli and Yang, Fei and Lu, Guiya and Li, Chunhong and Mo, Chune and Ou, Minglin and Hou, Xianliang},
title = {siRNA‐Based Nanodrug Delivery Systems in the Treatment of Autoimmune Diseases},
journal = {Journal of Immunology Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jimr/2307551}
}
EUVIMED